- Reports /
- Interleukin Inhibitors Market
Interleukin Inhibitors Market
Interleukin Inhibitors Market Market Research Report – Segmented By Type (IL-1, IL-5, IL-6, IL-17, IL-23, Other types), By Application (Psoriasis, Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications) & Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2027.
Table of contents
- Executive Summary
- Market Overview
- Industry Analysis
- Market Analysis
- By Type
- By Application
- North America
- Europe
- Asia-Pacific
- Middle-East & Africa
- Latin America
- Company Analysis
- Competitive Analysis
- Research Methodology
- Appendix
Executive Summary
Interleukin Inhibitors Market was valued at US $22.47 billion in 2021 and is projected to grow at 12.33% CAGR over the forecast period to reach US $45.14 billion by 2027. Interleukin Inhibitors Market represented US $4.66 billion opportunity over 2019-2021 and estimated to create US $22.68 billion opportunity in 2027 over 2021.
Interleukin Inhibitors from Consainsights analyses the Interleukin Inhibitors Market in the Life Sciences industry over the forecast period to 2027.
Interleukin Inhibitors research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.
Interleukin Inhibitors segmentation includes Type, Application and Geography.
Based on the Type, the Interleukin Inhibitors analysis covers IL-1, IL-5, IL-6, IL-17, IL-23, Other types.
In Type segment, IL-1 segment has highest cagr growth of 10.89%.
Based on the Application, the Interleukin Inhibitors analysis covers Psoriasis, Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications.
In Application segment, Psoriasis segment has highest cagr growth of 10.89%.
Based on the region, the Interleukin Inhibitors analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.
Key companies operating in the market include AbbVie, Inc, Sun Pharmaceutical Industries Limited, Johnson and Johnson, Novartis AG, Eli Lilly and Company, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceuticals Industries, Ltd, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.
Market Overview
Definition & Scope
The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.
Currency, Year & Forecast
The currency used in this report is USD, with the market size indicated in terms of USD million/billion.
For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.
Type
Introduction
In 2021, IL-1 segment has the highest revenue of US $8.79 billion and is expected to grow at CAGR of 10.89% by 2027 IL-1 segment has highest cagr growth of 10.89%.
IL-1
IL-1 segment was valued at US $6.97 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $17.66 billion by 2027. IL-1 segment represented US $1.82 billion opportunity over 2019-2021 and estimated to create US $8.87 billion opportunity in 2027 over 2021.
IL-5
IL-5 segment was valued at US $4.52 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $11.47 billion by 2027. IL-5 segment represented US $1.18 billion opportunity over 2019-2021 and estimated to create US $5.76 billion opportunity in 2027 over 2021.
IL-6
IL-6 segment was valued at US $2.12 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $5.36 billion by 2027. IL-6 segment represented US $0.55 billion opportunity over 2019-2021 and estimated to create US $2.69 billion opportunity in 2027 over 2021.
IL-17
IL-17 segment was valued at US $1.84 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $4.66 billion by 2027. IL-17 segment represented US $0.48 billion opportunity over 2019-2021 and estimated to create US $2.34 billion opportunity in 2027 over 2021.
IL-23
IL-23 segment was valued at US $1.34 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $3.39 billion by 2027. IL-23 segment represented US $0.35 billion opportunity over 2019-2021 and estimated to create US $1.70 billion opportunity in 2027 over 2021.
Other types
Other types segment was valued at US $1.03 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $2.60 billion by 2027. Other types segment represented US $0.27 billion opportunity over 2019-2021 and estimated to create US $1.31 billion opportunity in 2027 over 2021.
Application
Introduction
In 2021, Psoriasis segment has the highest revenue of US $10.23 billion and is expected to grow at CAGR of 10.89% by 2027 Psoriasis segment has highest cagr growth of 10.89%.
Psoriasis
Psoriasis segment was valued at US $8.11 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $20.56 billion by 2027. Psoriasis segment represented US $2.12 billion opportunity over 2019-2021 and estimated to create US $10.33 billion opportunity in 2027 over 2021.
Arthritis
Arthritis segment was valued at US $4.12 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $10.46 billion by 2027. Arthritis segment represented US $1.08 billion opportunity over 2019-2021 and estimated to create US $5.25 billion opportunity in 2027 over 2021.
Asthma
Asthma segment was valued at US $3.72 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $9.43 billion by 2027. Asthma segment represented US $0.97 billion opportunity over 2019-2021 and estimated to create US $4.74 billion opportunity in 2027 over 2021.
Inflammatory Bowel Disease (IBD)
Inflammatory Bowel Disease (IBD) segment was valued at US $1.48 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $3.75 billion by 2027. Inflammatory Bowel Disease (IBD) segment represented US $0.39 billion opportunity over 2019-2021 and estimated to create US $1.89 billion opportunity in 2027 over 2021.
Other Applications
Other Applications segment was valued at US $0.37 billion in 2019 and is projected to grow at 10.89% CAGR over the forecast period to reach US $0.94 billion by 2027. Other Applications segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.47 billion opportunity in 2027 over 2021.